Nautilus Biotechnolgy (NAUT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NAUT SEC filings page.
This page shows Nautilus Biotechnolgy, Inc. (NAUT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Research funding still drives the business, while lower spending narrows losses as a shrinking asset base makes liabilities more prominent.
Cash conversion was relatively close in FY2025: net loss was$59.0M while operating cash flow was-$50.7M , indicating the reported loss largely translated into cash outflow. Free cash flow was-$52.0M , slightly below operating cash flow, showing that capital spending added to the cash burden rather than losses being purely non-cash.
FY2025 research and development was
Total assets fell from
Financial Health Signals
We do not publish a peer-relative financial health score for Nautilus Biotechnolgy, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Nautilus Biotechnolgy, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Nautilus Biotechnolgy, Inc. reported a net loss of $59.0M while operations used $50.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nautilus Biotechnolgy, Inc. generated $234K in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 23.2%.
Nautilus Biotechnolgy, Inc. reported a net loss of $15.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Nautilus Biotechnolgy, Inc. earned -$0.12 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Nautilus Biotechnolgy, Inc. recorded an outflow of $14.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Nautilus Biotechnolgy, Inc. held $10.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Nautilus Biotechnolgy, Inc.'s gross margin was 89.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is down 2.4 percentage points.
Nautilus Biotechnolgy, Inc.'s quarterly ROE was -13.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 5.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.4 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Nautilus Biotechnolgy, Inc. invested $10.2M in research and development in Q3 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is up 5.9%.
Nautilus Biotechnolgy, Inc. invested $1.4M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 245.7% from the same quarter a year earlier. Against the prior quarter it is up 218.3%.
Not reported for Q3 2026.
NAUT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $234Kn/m | $190Kn/m | N/A | N/A | $0 | $0 | N/A | N/A |
| Cost of Revenue | $24Kn/m | $15Kn/m | N/A | N/A | $0 | $0 | N/A | N/A |
| Gross Profit | $210Kn/m | $175Kn/m | N/A | N/A | $0 | $0 | N/A | N/A |
| R&D Expenses | $10.2M+5.9% | $9.6M-7.5% | $9.7M-15.9% | $9.6M-25.3% | $9.6M-21.8% | $10.4M-16.4% | $11.5M-10.8% | $12.8M+2.9% |
| SG&A Expenses | $6.8M+15.4% | $6.3M-5.6% | $6.4M-12.2% | $5.8M-18.3% | $5.9M-13.9% | $6.7M-19.8% | $7.3M-15.8% | $7.2M-5.0% |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Net Income | -$15.6Mn/m | -$14.5Mn/m | -$14.7Mn/m | -$13.8Mn/m | -$13.6Mn/m | -$15.0Mn/m | -$16.6Mn/m | -$17.6Mn/m |
| EPS (Basic) | -$0.12n/m | -$0.11n/m | -$0.12n/m | -$0.11n/m | -$0.11n/m | -$0.12n/m | -$0.13n/m | -$0.14n/m |
| EPS (Diluted) | -$0.12n/m | -$0.11n/m | -$0.12n/m | -$0.11n/m | -$0.11n/m | -$0.12n/m | -$0.13n/m | -$0.14n/m |
| Diluted Shares (Avg) | 127M+0.7% | 127M+0.7% | 127M+0.4% | N/A | 126M+0.7% | 126M+0.7% | 126M+0.8% | N/A |
Not reported in any period shown, so not listed: Operating Income, EBITDA, Interest Expense.
NAUT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $148.9M-25.9% | $163.6M-23.3% | $177.8M-21.9% | $191.1M-21.3% | $200.9M-22.6% | $213.2M-21.8% | $227.7M-21.1% | $242.7M-20.6% |
| Current Assets | $90.2M-32.8% | $87.6M-41.9% | $98.8M-30.2% | $106.0M-20.2% | $134.3M-6.9% | $150.7M-11.8% | $141.6M-23.5% | $132.8M-24.9% |
| Cash & Equivalents | $10.5M-56.2% | $13.2M-61.8% | $14.6M-56.0% | $12.4M-55.2% | $23.9M+441.5% | $34.5M+38.5% | $33.2M+29.2% | $27.6M+42.5% |
| Short-Term Investments | $76.1M-29.2% | $70.9M-37.5% | $81.2M-23.0% | $91.0M-11.0% | $107.6M-21.0% | $113.4M-20.4% | $105.6M-32.2% | $102.2M-33.6% |
| Inventory | $900K | $600K | $300K | N/A | N/A | N/A | N/A | N/A |
| Long-Term Investments | $27.8M-25.1% | $45.2M+42.7% | $47.5M-12.1% | $52.7M-31.0% | $37.1M-54.0% | $31.6M-51.7% | $54.0M-18.5% | $76.4M-15.7% |
| Total Liabilities | $32.4M+1.9% | $32.5M+1.1% | $33.4M+0.3% | $34.1M+0.4% | $31.8M-12.4% | $32.1M-14.3% | $33.3M-15.1% | $34.0M-15.4% |
| Current Liabilities | $9.8M+8.6% | $8.6M+6.2% | $8.3M+2.3% | $8.0M+4.2% | $9.0M+3.7% | $8.1M-6.3% | $8.2M-11.5% | $7.6M-16.3% |
| Non-Current Liabilities | $22.6M-0.8% | $23.8M-0.6% | $25.0M-0.3% | $26.2M-0.7% | $22.8M-17.4% | $24.0M-16.8% | $25.1M-16.2% | $26.4M-15.1% |
| Total Equity | $116.6M-31.1% | $131.1M-27.6% | $144.4M-25.7% | $157.0M-24.8% | $169.1M-24.3% | $181.1M-23.0% | $194.4M-22.1% | $208.7M-21.3% |
| Retained Earnings | -$376.8Mn/m | -$361.2Mn/m | -$346.7Mn/m | -$332.0Mn/m | -$318.2Mn/m | -$304.7Mn/m | -$289.6Mn/m | -$273.0Mn/m |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
NAUT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.3Mn/m | -$13.7Mn/m | -$13.1Mn/m | -$12.4Mn/m | -$11.0Mn/m | -$13.3Mn/m | -$13.9Mn/m | -$14.3Mn/m |
| Depreciation & Amortization | $200K-50.0% | $300K-25.0% | $334K-28.2% | $400K-12.5% | $400K-20.0% | $400K-20.0% | $465K-9.9% | $457K-17.7% |
| Stock-Based Compensation | N/A | N/A | $1.4M-37.2% | N/A | N/A | N/A | $2.2M-30.4% | N/A |
| Capital Expenditures | $1.4M+245.7% | $454K+14.6% | $510K+132.9% | $244K-3.9% | $418K-41.0% | $396K-22.7% | $219K-66.2% | $254K-38.5% |
| Free Cash Flow | -$14.7Mn/m | -$14.2Mn/m | -$13.6Mn/m | -$12.6Mn/m | -$11.5Mn/m | -$13.7Mn/m | -$14.2Mn/m | -$14.6Mn/m |
| Investing Cash Flow | $10.4M+2209.3% | $12.0M-16.9% | $14.2M-27.1% | $787K-97.9% | $452Kn/m | $14.5M+1.3% | $19.5M-12.7% | $37.1Mn/m |
| Financing Cash Flow | $26Kn/m | $244K+156.8% | $1.1M+6038.9% | $101K-77.0% | $0-100.0% | $95K-70.2% | $18K-92.7% | $440K+73.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NAUT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.7% | 92.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -6682.1% | -7615.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -13.4%-5.4pp | -11.0%-2.7pp | -10.2%-1.6pp | -8.8%-0.4pp | -8.0%-0.7pp | -8.3%-0.7pp | -8.5%-1.0pp | -8.4%-2.0pp |
| Return on Assets | -10.5%-3.7pp | -8.8%-1.8pp | -8.3%-1.0pp | -7.2%0.0pp | -6.8%-0.4pp | -7.0%-0.4pp | -7.3%-0.8pp | -7.2%-1.7pp |
| Current Ratio | 9.25-5.7x | 10.14-8.4x | 11.85-5.5x | 13.33-4.1x | 14.95-1.7x | 18.52-1.2x | 17.36-2.7x | 17.40-2.0x |
| Liabilities-to-Equity | 0.28+0.1x | 0.25+0.1x | 0.23+0.1x | 0.22+0.1x | 0.190.0x | 0.180.0x | 0.170.0x | 0.160.0x |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | N/A | 0.00 | 0.00 | N/A | N/A |
| FCF Margin | -6293.2% | -7463.2% | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Operating Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. NAUT | FY2025 | N/A | -$59.0M | N/A | $291.7M | — |
| Turn Therapeutics Inc. TTRX | FY2025 | N/A | -$3.2M | N/A | $297.6M | — |
| Century Therapeutics, Inc. IPSC | FY2025 | $109.2M | -$9.6M | -8.8% | $302.4M | 60/100 |
| Fulcrum Therapeutics, Inc. FULC | FY2025 | $0 | -$74.9M | N/A | $288.0M | — |
| SAB Biotherapeutics, Inc. SABS | FY2025 | $0 | $13.3M | N/A | $289.3M | — |
| Rocket Pharmaceuticals, Inc. RCKT | FY2025 | $0 | -$223.1M | N/A | $286.5M | — |
Where Nautilus Biotechnolgy, Inc. Ranks
Frequently Asked Questions
No, Nautilus Biotechnolgy, Inc. (NAUT) reported a net loss of $58.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $59.0M.
Nautilus Biotechnolgy, Inc. (NAUT) has a return on equity of -37.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Nautilus Biotechnolgy, Inc. (NAUT) recorded an outflow of $52.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Nautilus Biotechnolgy, Inc. (NAUT) recorded an outflow of $50.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Nautilus Biotechnolgy, Inc. (NAUT) had $191.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Nautilus Biotechnolgy, Inc. (NAUT) invested $1.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Nautilus Biotechnolgy, Inc. (NAUT) invested $41.1M in research and development during fiscal year 2025.
Nautilus Biotechnolgy, Inc. (NAUT) had a current ratio of 13.33 as of fiscal year 2025, which is generally considered healthy.
Nautilus Biotechnolgy, Inc. (NAUT) had a liabilities-to-equity ratio of 0.22 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Nautilus Biotechnolgy, Inc. (NAUT) had a return on assets of -30.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Nautilus Biotechnolgy, Inc. (NAUT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $291.7M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Nautilus Biotechnolgy, Inc. (NAUT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $291.7M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Nautilus Biotechnolgy, Inc. (NAUT) held $156.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $50.7M over that year. Dividing the one by the other, the reported balance equals about 37 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Nautilus Biotechnolgy, Inc. (NAUT) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Nautilus Biotechnolgy, Inc. (NAUT) reported a net loss of $59.0M while operations used $50.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.